WO2007075475A2 - Gastric reflux resistant dosage forms - Google Patents

Gastric reflux resistant dosage forms Download PDF

Info

Publication number
WO2007075475A2
WO2007075475A2 PCT/US2006/048029 US2006048029W WO2007075475A2 WO 2007075475 A2 WO2007075475 A2 WO 2007075475A2 US 2006048029 W US2006048029 W US 2006048029W WO 2007075475 A2 WO2007075475 A2 WO 2007075475A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
natural polymer
film
weight
gastric
Prior art date
Application number
PCT/US2006/048029
Other languages
French (fr)
Other versions
WO2007075475A3 (en
Inventor
Nachiappan Chidambaram
Original Assignee
Banner Pharmacaps, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banner Pharmacaps, Inc. filed Critical Banner Pharmacaps, Inc.
Priority to CA2633924A priority Critical patent/CA2633924C/en
Priority to EP06845613.6A priority patent/EP1973533B1/en
Priority to JP2008547361A priority patent/JP5627854B2/en
Priority to ES06845613.6T priority patent/ES2549858T3/en
Priority to EP15163491.2A priority patent/EP2923696B1/en
Publication of WO2007075475A2 publication Critical patent/WO2007075475A2/en
Publication of WO2007075475A3 publication Critical patent/WO2007075475A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Definitions

  • the invention is in the field of gastric resistant dosage forms.
  • CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. S .N. 11/316,830 filed in the
  • enteric dosage forms are well known in the art. Such dosage forms are described in Remington's Pharmaceutical Sciences, 18 th Ed., Mack Publishing Co., Easton, PA (1990). Enteric dosage forms are useful for protecting the contents of the dosage form from the gastric conditions of the stomach and/or to protect gastric tissue from an irritant material contained in the dosage form. Enteric dosage forms can also be useful in preventing gastric reflux due to the presence of odor-causing liquids, such as fish oil or garlic oil, in the dosage form.
  • Enteric-coated dosage forms are typically produced by a film coating process, where a thin film layer of an acid-insoluble (enteric) polymer is applied to the surface of a pre-manufactured dosage form, such as a tablet, and to a lesser extent hard and soft capsules.
  • the enteric coating method involves spraying an aqueous or organic solution or suspension of one or more enteric polymers onto tumbling or moving tablets or capsules, followed by drying at elevated temperatures.
  • Enteric dosage forms made by this coating method can suffer from various process-related problems that affect the performance and/or appearance of the coating. For example, "orange peel" surface formation, also known as surface roughness or mottling, may result.
  • coat integrity failure may occur, such as cracking or flaking off of the enteric polymer coating.
  • All coating processes present inherent problems, including possible uneven distribution of the coating ingredients, which can occur under multivariate coating processes. These problems are common to all enteric dosage forms.
  • the problems faced during the coating of gelatin or polysaccharide capsules are even more critical due to the delicate and heat sensitive nature of the soft elastic capsule shell. Both hard and soft capsules can undergo thermally induced agglomeration and distortion of the capsule shell.
  • the smoothness and elasticity of the capsule surface makes it difficult to form an intact adhering enteric coating, without a subcoating step to improve the surface of the capsule for coating.
  • enteric coatings cause the loss of the normally shiny and clear appearance of gelatin capsule shells, which is a major reason for the popularity and acceptance of gelatin capsules.
  • WO 2004/03068 by Banner Pharmacaps, Inc. (“the '068 application”) describes a gel mass that is useful in manufacturing enteric soft or hard shell capsules or enteric tablets without the need for a coating.
  • the gel mass contains a film-forming, water-soluble polymer, an acid-insoluble polymer and optionally, one or more excipients such as plasticizers, colorants and flavorants.
  • the '068 application discloses the use of synthetic acid-insoluble polymers such as cellulosic polymers and acrylic acid-methacrylic acid copolymers (EUDRAGIT®) which are present in a concentration from 8 to 20% by weight of the wet gel mass.
  • EUDRAGIT® acrylic acid-methacrylic acid copolymers
  • U.S. Patent Application Publication No. 2003/0175335 by Scott et al. (“the '335 application”) describes film forming compositions containing pectin, at least one film-forming polymer, and a setting system for preparing soft and hard shell capsules.
  • the concentration of pectin is 5 to 60% by weight, preferably 10 to 40% by weight.
  • the concentration of the film- forming polymer is 40 to 95% by weight, preferably 50 to 85% by weight.
  • the '335 application discloses a film containing 5 to 25%, preferably 10 to 20% by weight pectin which is suitable to prepare hard shell capsules with enteric properties.
  • Gastric resistant film-forming compositions containing a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent are described herein.
  • the compositions can be used for drug delivery either as a liquid or as a gelled capsule.
  • Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers.
  • the concentration of the gastric resistant natural polymer is less than about 5% by weight of the composition, preferably from about 2 to about 4% by weight of the composition.
  • Suitable film-forming natural polymers include gelatin and gelatin-like polymers.
  • the concentration of the film-forming natural polymer is from about 20 to about 40% by weight of the composition, preferably from about 25 to about 40% by weight of the composition.
  • Suitable gelling agents include divalent cations such as Ca 2+ and Mg 2+ .
  • the concentration of the optional gelling agent is less than about 2% by weight of the composition, preferably less than about 1% by weight of the composition.
  • the composition can further contain one or more plasticizers to facilitate the film-forming process.
  • the film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (SOFTLET®) containing an active agent and one or more pharmaceutically acceptable excipients.
  • the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition.
  • the compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form as well as esophageal irritation due to the reflux of irritant drugs delivered orally.
  • Gastric resistant natural polymer refers to natural polymers or mixtures of natural polymers which are insoluble in the acidic pH of the stomach.
  • “Film-forming natural polymer” refers to polymers useful for surface coatings that are applied by spraying, brushing, or various industrial processes, which undergo film formation. In most film-formation processes, a liquid coating oT relatively low viscosity is applied to a solid substrate and is cured to a solid, high-molecular- weight, polymer-based adherent film possessing the properties desired by the user. For most common applications, this film has a thickness ranging from 0.5 to 500 micrometers (0.0005 to 0.5 millimeters, or 0.00002 to 0.02 inches).
  • “Gelling agent” refers to substances that undergo a high degree of cross-linking or association when hydrated and dispersed in the dispersing medium, or when dissolved in the dispersing medium. This cross-linking or association of the dispersed phase alters the viscosity of the dispersing medium. The movement of the dispersing medium is restricted by the dispersed phase, and the viscosity is increased.
  • Gastric resistant film-forming compositions containing (1) a gastric resistant natural polymer; (2) a film-forming natural polymer; and optionally (3) a gelling agent, are described herein.
  • gastric resistant natural polymers include, but are not limited to, pectin and pectin-like polymers which typically consist mainly of galacturonic acid and galacturonic acid methyl ester units forming linear polysaccharide chains.
  • these polysaccharides are rich in galacturonic acid, rhamnose, arabinose and galactose, for example the polygalacturonans, rhamnogalacturonans and some arabinans, galactans and arabinogalactans. These are normally classified according to the degree of esterif ⁇ cation.
  • HM high (methyl) ester
  • a relatively high portion of the carboxyl groups occur as methyl esters, and the remaining carboxylic acid groups are in the form of the free acid or as its ammonium, potassium, calcium or sodium salt.
  • Useful properties may vary with the degree of esterification and with the degree of polymerization.
  • Pectin in which less than 50% of the carboxyl acid units occur as the methyl ester, is normally referred to as low (methyl) ester or LM-pectin.
  • low ester pectin is obtained from high ester pectin by treatment at mild acidic or alkaline conditions.
  • Amidated pectin is obtained from high ester pectin when ammonia is used in the alkaline deesterification process. In this type of pectin some of the remaining carboxylic acid groups have been transformed into the acid amide.
  • the useful properties of amidated pectin may vary with the proportion of ester and amide units and with the degree of polymerization.
  • the gastric resistant natural polymer is pectin.
  • the gastric resistant natural polymer is present in an amount less than about 5% by weight of the composition, preferably from about 2 to about 4% by weight of the composition.
  • Exemplary film-forming natural polymers include, but are not limited to, gelatin and gelatin-like polymers.
  • the film- forming natural polymer is gelatin. A number of other gelatin-like polymers are available commercially.
  • the film-forming natural polymer is present in an amount from about 20 to about 40% by weight of the composition, preferably from about 25 to about 40% by weight of the composition.
  • compositions can optionally contain a gelling agent.
  • exemplary gelling agents include divalent cations such as Ca 2+ and Mg 2+ .
  • Sources of these ions include inorganic calcium and magnesium salts and calcium gelatin.
  • the gelling agent is present in an amount less than about 2% by weight of the composition, preferably less than about 1% by weight of the composition. D. Plasticizers
  • plasticizers can be added to the composition to facilitate the film-forming process.
  • Suitable plasticizers include glycerin, sorbitol, sorbitans, maltitol, glycerol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate and combinations thereof.
  • the concentration of the one or more plasticizers is from about 8% to about 30% by weight of the composition.
  • the plasticizer is glycerin and/or sorbitol. III.
  • the film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (SOFTLET®) containing an active agent and one or more pharmaceutically acceptable excipients.
  • the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition.
  • the film-forming composition can be used to prepare soft or hard capsules using techniques well known in the art.
  • soft capsules are typically produced using a rotary die encapsulation process.
  • Fill formulations are fed into the encapsulation machine by gravity.
  • the capsule shell can contain one or more plasticizers selected from the group consisting of glycerin, sorbitol, sorbitans, maltitol, glycerol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate and combinations thereof.
  • plasticizers selected from the group consisting of glycerin, sorbitol, sorbitans, maltitol, glycerol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate and combinations thereof.
  • the capsule shell can include other suitable shell additives such as opacifiers, colorants, humectants, preservatives, flavorings, and buffering salts and acids.
  • suitable shell additives such as opacifiers, colorants, humectants, preservatives, flavorings, and buffering salts and acids.
  • Opacifiers are used to opacify the capsule shell when the encapsulated active agents are light sensitive.
  • Suitable opacifiers include titanium dioxide, zinc oxide, calcium carbonate and combinations thereof.
  • Colorants can be used to for marketing and product identification/differentiation purposes. Suitable colorants include synthetic and natural dyes and combinations thereof.
  • Humectants can be used to suppress the water activity of the softgel. Suitable humectants include glycerin and sorbitol, which are often components of the plasticizer composition. Due to the low water activity of dried, properly stored softgels, the greatest risk from microorganisms comes from molds and yeasts. For this reason, preservatives can be incorporated into the capsule shell. Suitable preservatives include alkyl esters of p- hydroxy benzoic acid such as methyl, ethyl, propyl, butyl and heptyl (collectively known as "parabens") or combinations thereof.
  • parabens alkyl esters of p- hydroxy benzoic acid
  • Flavorings can be used to mask unpleasant odors and tastes of fill formulations. Suitable flavorings include synthetic and natural flavorings. The use of flavorings can be problematic due to the presence of aldehydes which can cross-link gelatin. As a result, buffering salts and acids can be used in conjunction with flavorings that contain aldehydes in order to inhibit cross-linking of the gelatin.
  • Agents Soft or hard capsules can used to deliver a wide variety of pharmaceutically active agents. Suitable agents include analgesics, anti- inflammatory agents, antihelmintics, anti-arrhythmic agents, anti-bacterial agents, anti-viral agents, anti-hypertensive agents, anti-coagulants, antidepressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-malarials, anti-migraine agents, anti —muscarinic agents, antineoplastic agents, erectile dysfunction improvement agents, immunosupressants, anti-protozoal agents, anti-thyroid agents, anxiolytic agents, sedatives, hypnotics, neuroleptics, -blockers, cardiac inotropic agents, corticosteroids, diuretics, antiparkinsonian agents, gastro-intestinal agents, histamine Hi and H2 receptor antagonists, keratolytics, lipid regulating agents, anti-anginal
  • Typical fill materials include, but are not limited to, fish oil, garlic . oil, soybean oil, peppermint oil, eucalyptus oil, horse chestnut seed extract, valproic acid, proton pump inhibitors, probiotics, and medium chain triglycerides ("MCT").
  • MCT medium chain triglycerides
  • Fill formulations may be prepared using a pharmaceutically acceptable carrier composed of materials that are considered safe and effective and may be administered to an individual without causing undesirable biological side effects or unwanted interactions.
  • the carrier is all components present in the pharmaceutical formulation other than the active ingredient or ingredients.
  • carrier includes, but is not limited to surfactants, humectants, plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, solubilizers, bioavailability enhancers, pH adjusting agents, and combinations thereof.
  • the composition can be administered as a liquid with an active agent dissolved (e.g. solution) or dispersed (e.g. suspension) in the composition.
  • active agents are described above.
  • the solution or suspension may be prepared using one or more pharmaceutically acceptable excipients.
  • Suitable excipients include, but are not limited to, surfactants, humectants, plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, solubilizers, bioavailability enhancers, pH adjusting agents, f ⁇ avorants and combinations thereof. Examples
  • composition of the gastric resistant dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.
  • composition of the gastric dosage form is shown below.

Abstract

Gastric resistant film-forming compositions are described herein. The composition contains a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (SOFTLET®) containing an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally.

Description

GASTRIC REFLUX RESISTANT DOSAGE FORMS FIELD OF THE INVENTION
The invention is in the field of gastric resistant dosage forms. CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. S .N. 11/316,830 filed in the
U.S. Patent and Trademark Office on 22 December 2005.
BACKGROUND OF THE INVENTION
The use and manufacture of enteric dosage forms are well known in the art. Such dosage forms are described in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990). Enteric dosage forms are useful for protecting the contents of the dosage form from the gastric conditions of the stomach and/or to protect gastric tissue from an irritant material contained in the dosage form. Enteric dosage forms can also be useful in preventing gastric reflux due to the presence of odor-causing liquids, such as fish oil or garlic oil, in the dosage form.
Enteric-coated dosage forms are typically produced by a film coating process, where a thin film layer of an acid-insoluble (enteric) polymer is applied to the surface of a pre-manufactured dosage form, such as a tablet, and to a lesser extent hard and soft capsules. The enteric coating method involves spraying an aqueous or organic solution or suspension of one or more enteric polymers onto tumbling or moving tablets or capsules, followed by drying at elevated temperatures. Enteric dosage forms made by this coating method can suffer from various process-related problems that affect the performance and/or appearance of the coating. For example, "orange peel" surface formation, also known as surface roughness or mottling, may result. More seriously, coat integrity failure may occur, such as cracking or flaking off of the enteric polymer coating. All coating processes present inherent problems, including possible uneven distribution of the coating ingredients, which can occur under multivariate coating processes. These problems are common to all enteric dosage forms. However, the problems faced during the coating of gelatin or polysaccharide capsules are even more critical due to the delicate and heat sensitive nature of the soft elastic capsule shell. Both hard and soft capsules can undergo thermally induced agglomeration and distortion of the capsule shell. Moreover, the smoothness and elasticity of the capsule surface makes it difficult to form an intact adhering enteric coating, without a subcoating step to improve the surface of the capsule for coating. Finally, enteric coatings cause the loss of the normally shiny and clear appearance of gelatin capsule shells, which is a major reason for the popularity and acceptance of gelatin capsules.
Attempts to overcome the limitations associated with coated dosage forms have been made. For example, WO 2004/03068 by Banner Pharmacaps, Inc. ("the '068 application") describes a gel mass that is useful in manufacturing enteric soft or hard shell capsules or enteric tablets without the need for a coating. The gel mass contains a film-forming, water-soluble polymer, an acid-insoluble polymer and optionally, one or more excipients such as plasticizers, colorants and flavorants. The '068 application, however, discloses the use of synthetic acid-insoluble polymers such as cellulosic polymers and acrylic acid-methacrylic acid copolymers (EUDRAGIT®) which are present in a concentration from 8 to 20% by weight of the wet gel mass.
U.S. Patent Application Publication No. 2003/0175335 by Scott et al. ("the '335 application") describes film forming compositions containing pectin, at least one film-forming polymer, and a setting system for preparing soft and hard shell capsules. The concentration of pectin is 5 to 60% by weight, preferably 10 to 40% by weight. The concentration of the film- forming polymer is 40 to 95% by weight, preferably 50 to 85% by weight. The '335 application discloses a film containing 5 to 25%, preferably 10 to 20% by weight pectin which is suitable to prepare hard shell capsules with enteric properties.
There exists a need for a gastric resistant film-forming composition that contains a gastric resistant natural polymer at relatively low concentrations.
Therefore, it is an object of the invention to provide a gastric resistant film-forming composition containing a gastric resistant film-forming composition which contains a gastric resistant natural polymer at relatively low concentrations and methods of manufacturing thereof.
It is further an object of the invention to provide a gastric resistant capsule shell, which can encapsulate a liquid, semi-solid, or solid fill, which contains a gastric resistant natural polymer at relatively low concentrations and methods of manufacturing thereof.
BRIEF SUMMARY OF THE INVENTION Gastric resistant film-forming compositions containing a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent are described herein. The compositions can be used for drug delivery either as a liquid or as a gelled capsule. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The concentration of the gastric resistant natural polymer is less than about 5% by weight of the composition, preferably from about 2 to about 4% by weight of the composition. Suitable film-forming natural polymers include gelatin and gelatin-like polymers. The concentration of the film-forming natural polymer is from about 20 to about 40% by weight of the composition, preferably from about 25 to about 40% by weight of the composition. Suitable gelling agents include divalent cations such as Ca2+ and Mg2+. The concentration of the optional gelling agent is less than about 2% by weight of the composition, preferably less than about 1% by weight of the composition. The composition can further contain one or more plasticizers to facilitate the film-forming process.
The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (SOFTLET®) containing an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form as well as esophageal irritation due to the reflux of irritant drugs delivered orally. DETAILED DESCRIPTION OF THE INVENTION I. Definitions
"Gastric resistant natural polymer", as used herein, refers to natural polymers or mixtures of natural polymers which are insoluble in the acidic pH of the stomach.
"Film-forming natural polymer", as used herein, refers to polymers useful for surface coatings that are applied by spraying, brushing, or various industrial processes, which undergo film formation. In most film-formation processes, a liquid coating oT relatively low viscosity is applied to a solid substrate and is cured to a solid, high-molecular- weight, polymer-based adherent film possessing the properties desired by the user. For most common applications, this film has a thickness ranging from 0.5 to 500 micrometers (0.0005 to 0.5 millimeters, or 0.00002 to 0.02 inches).
"Gelling agent", as used herein, refers to substances that undergo a high degree of cross-linking or association when hydrated and dispersed in the dispersing medium, or when dissolved in the dispersing medium. This cross-linking or association of the dispersed phase alters the viscosity of the dispersing medium. The movement of the dispersing medium is restricted by the dispersed phase, and the viscosity is increased. II. Composition
Gastric resistant film-forming compositions containing (1) a gastric resistant natural polymer; (2) a film-forming natural polymer; and optionally (3) a gelling agent, are described herein.
A. Gastric Resistant Natural Polymers Exemplary gastric resistant natural polymers include, but are not limited to, pectin and pectin-like polymers which typically consist mainly of galacturonic acid and galacturonic acid methyl ester units forming linear polysaccharide chains. Typically these polysaccharides are rich in galacturonic acid, rhamnose, arabinose and galactose, for example the polygalacturonans, rhamnogalacturonans and some arabinans, galactans and arabinogalactans. These are normally classified according to the degree of esterifϊcation. In high (methyl) ester ("HM") pectin, a relatively high portion of the carboxyl groups occur as methyl esters, and the remaining carboxylic acid groups are in the form of the free acid or as its ammonium, potassium, calcium or sodium salt. Useful properties may vary with the degree of esterification and with the degree of polymerization. Pectin, in which less than 50% of the carboxyl acid units occur as the methyl ester, is normally referred to as low (methyl) ester or LM-pectin. In general, low ester pectin is obtained from high ester pectin by treatment at mild acidic or alkaline conditions. Amidated pectin is obtained from high ester pectin when ammonia is used in the alkaline deesterification process. In this type of pectin some of the remaining carboxylic acid groups have been transformed into the acid amide. The useful properties of amidated pectin may vary with the proportion of ester and amide units and with the degree of polymerization. In one embodiment, the gastric resistant natural polymer is pectin.
The gastric resistant natural polymer is present in an amount less than about 5% by weight of the composition, preferably from about 2 to about 4% by weight of the composition.
B. Film-Forming Natural Polymers . Exemplary film-forming natural polymers include, but are not limited to, gelatin and gelatin-like polymers. In a preferred embodiment, the film- forming natural polymer is gelatin. A number of other gelatin-like polymers are available commercially. The film-forming natural polymer is present in an amount from about 20 to about 40% by weight of the composition, preferably from about 25 to about 40% by weight of the composition.
C. Gelling Agent
The compositions can optionally contain a gelling agent. Exemplary gelling agents include divalent cations such as Ca2+ and Mg2+. Sources of these ions include inorganic calcium and magnesium salts and calcium gelatin. The gelling agent is present in an amount less than about 2% by weight of the composition, preferably less than about 1% by weight of the composition. D. Plasticizers
One or more plasticizers can be added to the composition to facilitate the film-forming process. Suitable plasticizers include glycerin, sorbitol, sorbitans, maltitol, glycerol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate and combinations thereof. The concentration of the one or more plasticizers is from about 8% to about 30% by weight of the composition. In one embodiment, the plasticizer is glycerin and/or sorbitol. III. Method of Making The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (SOFTLET®) containing an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition.
A. Capsules
1. Shell
The film-forming composition can be used to prepare soft or hard capsules using techniques well known in the art. For example, soft capsules are typically produced using a rotary die encapsulation process. Fill formulations are fed into the encapsulation machine by gravity.
The capsule shell can contain one or more plasticizers selected from the group consisting of glycerin, sorbitol, sorbitans, maltitol, glycerol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate and combinations thereof.
In addition to the plasticizer(s), the capsule shell can include other suitable shell additives such as opacifiers, colorants, humectants, preservatives, flavorings, and buffering salts and acids.
Opacifiers are used to opacify the capsule shell when the encapsulated active agents are light sensitive. Suitable opacifiers include titanium dioxide, zinc oxide, calcium carbonate and combinations thereof. Colorants can be used to for marketing and product identification/differentiation purposes. Suitable colorants include synthetic and natural dyes and combinations thereof.
Humectants can be used to suppress the water activity of the softgel. Suitable humectants include glycerin and sorbitol, which are often components of the plasticizer composition. Due to the low water activity of dried, properly stored softgels, the greatest risk from microorganisms comes from molds and yeasts. For this reason, preservatives can be incorporated into the capsule shell. Suitable preservatives include alkyl esters of p- hydroxy benzoic acid such as methyl, ethyl, propyl, butyl and heptyl (collectively known as "parabens") or combinations thereof.
Flavorings can be used to mask unpleasant odors and tastes of fill formulations. Suitable flavorings include synthetic and natural flavorings. The use of flavorings can be problematic due to the presence of aldehydes which can cross-link gelatin. As a result, buffering salts and acids can be used in conjunction with flavorings that contain aldehydes in order to inhibit cross-linking of the gelatin.
2. Fill Material i. Agents Soft or hard capsules can used to deliver a wide variety of pharmaceutically active agents. Suitable agents include analgesics, anti- inflammatory agents, antihelmintics, anti-arrhythmic agents, anti-bacterial agents, anti-viral agents, anti-hypertensive agents, anti-coagulants, antidepressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-malarials, anti-migraine agents, anti —muscarinic agents, antineoplastic agents, erectile dysfunction improvement agents, immunosupressants, anti-protozoal agents, anti-thyroid agents, anxiolytic agents, sedatives, hypnotics, neuroleptics, -blockers, cardiac inotropic agents, corticosteroids, diuretics, antiparkinsonian agents, gastro-intestinal agents, histamine Hi and H2 receptor antagonists, keratolytics, lipid regulating agents, anti-anginal agents, nutritional agents, opioid analgesics, sex hormones, stimulants, muscle relaxants, anti-osteoporosis agents, anti- obesity agents, cognition enhancers, anti-urinary incontinence agents, nutritional oils, anti-benign prostate hypertrophy agents, essential fatty acids, non essential fatty acids, vitamins, minerals and mixtures thereof.
Typical fill materials include, but are not limited to, fish oil, garlic . oil, soybean oil, peppermint oil, eucalyptus oil, horse chestnut seed extract, valproic acid, proton pump inhibitors, probiotics, and medium chain triglycerides ("MCT"). ii. Excipients
Fill formulations may be prepared using a pharmaceutically acceptable carrier composed of materials that are considered safe and effective and may be administered to an individual without causing undesirable biological side effects or unwanted interactions. The carrier is all components present in the pharmaceutical formulation other than the active ingredient or ingredients. As generally used herein "carrier" includes, but is not limited to surfactants, humectants, plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, solubilizers, bioavailability enhancers, pH adjusting agents, and combinations thereof. B. Solutions and Suspensions
Alternatively, the composition can be administered as a liquid with an active agent dissolved (e.g. solution) or dispersed (e.g. suspension) in the composition. Suitable active agents are described above. The solution or suspension may be prepared using one or more pharmaceutically acceptable excipients. Suitable excipients include, but are not limited to, surfactants, humectants, plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, solubilizers, bioavailability enhancers, pH adjusting agents, fϊavorants and combinations thereof. Examples
The following film-forming compositions were used to prepare stable soft gelatin capsules using techniques well known in the art. Example 1. Gastric Resistant Dosage Form
The composition of the gastric resistant dosage form is shown below.
Figure imgf000010_0001
Example 4. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Component % by weight of the composition
Pectin 4.04
Water 70.71
Calcium chloride (CaCl2) 0.03
Gelatin (150 bloom bovine bone) 17.75
Glycerin 7.43
Example 5. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Component % by weight of the composition
Pectin 4.04
Water 70.71
Calcium chloride (CaCl2) 0.01
Gelatin (150 bloom bovine bone) 17.77
Glycerin 7.43
Example 6. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000011_0001
Example 7. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000012_0001
Example 8. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000012_0002
Example 9. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000012_0003
Example 10. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000013_0001
Example 11. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000013_0002
Example 12. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000013_0003
Example 13. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000014_0001
Example 14. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000014_0002
Example 16. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000015_0001
Example 17. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000015_0002
Example 18. Gastric Resistant Dosage Form
The composition of the gastric dosage form is shown below.
Figure imgf000015_0003
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs.

Claims

We claim:
1. A gastric resistant film-forming liquid composition comprising
(a) a gastric resistant natural polymer present in an amount less than about 5% by weight of the composition;
(b) a film-forming natural polymer; and
(c) optionally, a gelling agent.
2. The composition of claim 1, wherein the gastric resistant natural polymer is pectin.
3. The composition of claim 1, wherein the gastric resistant natural polymer is a pectin-like polymer.
4. The composition of claim 1, wherein the concentration of the gastric resistant natural polymer is from about 2 to about 4% by weight of the composition.
5. The composition of claim I5 wherein the film-forming natural polymer is gelatin.
6. The composition of claim 5, wherein the film-forming natural polymer is a gelatin-like polymer.
7. The composition of claim 1, wherein the concentration of the film- forming natural polymer is from about 20 to about 40% by weight of the composition.
8. The composition of claim 7, wherein the concentration of the film- forming natural polymer is from about 25 to about 40% by weight of the composition.
9. The composition of claim 1 comprising a gelling agent.
10. The composition of claim 9, wherein the gelling agent is divalent cations selected from the group consisting of calcium salts, magnesium salts, and calcium gelatin.
11. The composition of claim 1 comprising a gelling agent at a concentration of less than about 2% by weight of the composition.
12. The composition of claim 11, wherein the concentration of the gelling agent is less than about 1% by weight of the composition.
13. The composition of claim 1 further comprising one or more plasticizers selected from the group consisting of glycerin, sorbitol, sorbitans, maltitol, glycerol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate and combinations thereof.
14. The composition of claim 13, wherein the concentration of the one or more plasticizers is from about 8% to about 30% by weight of the composition.
15. The composition of claim 1 further comprising a therapeutic, prophylactic or diagnostic agent dissolved or dispersed in the gastric- resistant film-forming composition.
16. A gastric resistant protein or polysaccharide gelled composition comprising
(a) a gastric resistant natural polymer present in an amount less than about 5% by weight of the composition;
(b) a film-forming natural polymer; and
(c) a gelling agent.
17. The composition of claim 16, wherein the composition is a hard or soft capsule shell.
18. The composition of claim 16, wherein the gastric resistant natural polymer is pectin.
19. The composition of claim 16, wherein the gastric resistant natural polymer is a pectin-like polymer.
20. The composition of claim 16, wherein the concentration of the gastric resistant natural polymer is from about 2 to about 4% by weight of the composition.
21. The composition of claim 16, wherein the film-forming natural polymer is gelatin.
22. The composition of claim 16, wherein the film forming natural polymer is a gelatin-like polymer.
23. The composition of claim 16, wherein the concentration of the film forming natural polymer is from about 20 to about 40% by weight of the composition.
24. The composition of claim 22, wherein the concentration of the film coating natural polymer is from about 25 to about 40% by weight of the composition.
25. The composition of claim 16, wherein the gelling agent is a source of divalent cations selected from the group consisting of calcium salts, magnesium salts, and calcium gelatin.
26. The composition of claim 16, wherein the concentration of the gelling agent is less than about 2% by weight of the composition.
27. The composition of claim 26, wherein the concentration of the gelling agent is less than about 1% by weight of the composition.
28. The composition of claim 16 further comprising one or more plasticizers selected from the group consisting of glycerin, sorbitol, sorbitans, maltitol, glycerol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate and combinations thereof.
29. The composition of claim 28, wherein the concentration of the one or more plasticizers is from about 8% to about 30% by weight of the composition.
30. The composition of claim 17 further comprising a fill material
31. The composition of claim 30, wherein the fill material is in a form selected from the group consisting of liquid, semi-solid, and solid.
32. The composition of claim 30, wherein the fill material comprises one or more therapeutic, prophylactic or diagnostic agents and optionally one or more pharmaceutically acceptable excipients.
33. A method of manufacturing the gastric resistant protein or polysaccharide gelled composition of any one of claims 16-32 the method comprising (a) preparing a solution comprising a film-forming natural polymer and a gastric-resistant natural polymer and optionally one or more plasticizers to form a gel mass; and
(b) casting the gel mass into films or ribbons.
34. A method of manufacturing a gastric resistant protein or polysaccharide gelled capsule composition comprising the composition of any one of claims 16-32, the method comprising
(a) preparing a solution comprising a film-forming natural polymer and a gastric-resistant natural polymer and mixing and optionally one or more plasticizers to form a gel mass;
(b) casting the gel mass into films or ribbons; and
(c) forming a capsule shell.
PCT/US2006/048029 2005-12-22 2006-12-18 Gastric reflux resistant dosage forms WO2007075475A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2633924A CA2633924C (en) 2005-12-22 2006-12-18 Gastric reflux resistant dosage forms
EP06845613.6A EP1973533B1 (en) 2005-12-22 2006-12-18 Gastric reflux resistant dosage forms
JP2008547361A JP5627854B2 (en) 2005-12-22 2006-12-18 Gastric reflux resistant dosage form
ES06845613.6T ES2549858T3 (en) 2005-12-22 2006-12-18 Dosage forms resistant to gastric reflux
EP15163491.2A EP2923696B1 (en) 2005-12-22 2006-12-18 Gastric reflux resistant dosage forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/316,830 2005-12-22
US11/316,830 US20070148248A1 (en) 2005-12-22 2005-12-22 Gastric reflux resistant dosage forms

Publications (2)

Publication Number Publication Date
WO2007075475A2 true WO2007075475A2 (en) 2007-07-05
WO2007075475A3 WO2007075475A3 (en) 2007-12-13

Family

ID=38007176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048029 WO2007075475A2 (en) 2005-12-22 2006-12-18 Gastric reflux resistant dosage forms

Country Status (6)

Country Link
US (5) US20070148248A1 (en)
EP (3) EP2923696B1 (en)
JP (2) JP5627854B2 (en)
CA (2) CA2633924C (en)
ES (3) ES2538803T3 (en)
WO (1) WO2007075475A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013093630A2 (en) 2011-12-22 2013-06-27 Pronova Biopharma Norge As Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
US8975243B2 (en) 2005-11-12 2015-03-10 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2015066176A1 (en) 2013-10-30 2015-05-07 Banner Life Sciences, LLC Enteric soft capsules comprising polyunsaturated fatty acids
US9050368B2 (en) 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions
US9119863B2 (en) 2005-11-12 2015-09-01 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CN106456558A (en) * 2014-10-06 2017-02-22 富士胶囊股份有限公司 Method of producing enteric soft capsule
US9782374B2 (en) 2014-06-23 2017-10-10 Patheon Softgels Inc. All-natural enteric soft capsules
US9782347B2 (en) 2005-11-12 2017-10-10 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
EP3205339A4 (en) * 2014-10-06 2018-03-14 Fuji Capsule Co., Ltd. Method of producing enteric-coated seamless soft capsule
US20180353432A1 (en) * 2015-12-09 2018-12-13 Altergon S.A. SOFT GELATIN CAPSULES WITH pH-INDEPENDENT RELEASE
US10293052B2 (en) 2007-11-13 2019-05-21 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE487470T1 (en) * 2002-09-11 2010-11-15 Elan Pharma Int Ltd GEL-STABILIZED ACTIVE COMPOSITIONS IN NANOPARTICLE SIZE
WO2013155430A1 (en) * 2012-04-13 2013-10-17 Banner Pharmacaps, Inc. Soft elastic capsules containing tablets and liquid or semisolid fills and methods for their manufacture
JP2014172850A (en) * 2013-03-07 2014-09-22 Capsugel Belgium Nv Hard capsule formulation
CA2905365C (en) * 2013-03-15 2021-03-23 Banner Life Sciences Llc Silk-based capsules
GB2529599B (en) 2013-05-23 2017-02-15 Barlean's Organic Oils Llc Rotary die system
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
CN107072950B (en) 2014-09-11 2020-11-03 嘉利达股份有限公司 Gelatin/pectin particles
JP2017534630A (en) 2014-10-31 2017-11-24 バーリーンズ オーガニック オイルズ，エルエルシー Method and apparatus for producing a soft gel
CN105534945B (en) * 2015-12-29 2020-12-25 仙乐健康科技股份有限公司 Plant type enteric soft capsule
WO2023036581A1 (en) * 2021-09-13 2023-03-16 Nutrition & Biosciences Usa 1, Llc A film-forming composition comprising pectin
DE102022104553A1 (en) * 2022-02-25 2023-08-31 Gelita Ag Enteric-coated capsule and its use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888778A1 (en) * 1997-07-03 1999-01-07 Samyang Corporation Colon selective drug delivery system and compositions comprising said system
EP1132081A2 (en) * 2000-03-06 2001-09-12 Suheung Capsule Co Ltd. Process for preparing cellulose capsule using mixed solution of pectin and glycerin
WO2001070385A2 (en) * 2000-03-17 2001-09-27 Cycolor, Inc. Method for producing microcapsules having improved wall characteristics
US20030166508A1 (en) * 2000-06-07 2003-09-04 Junshou Zhang Biologically active oral preparation that can be site-specific released in colon
US20030175335A1 (en) * 2000-09-01 2003-09-18 Scott Robert Anthony Pectin film compositions
WO2004030658A1 (en) * 2002-10-01 2004-04-15 Banner Pharmacaps, Inc. Enteric composition for the manufacture of soft capsule wall
EP1518552A1 (en) * 2003-09-29 2005-03-30 Suheung Capsule Co Ltd. Fish gelatin hard capsule and its preparation method

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58172313A (en) 1982-04-01 1983-10-11 Morishita Jintan Kk Enteric soft capsule
JPS58194810A (en) * 1982-05-07 1983-11-12 Morishita Jintan Kk Coated soft miniature capsule
US4719112A (en) 1982-10-29 1988-01-12 Warner-Lambert Company Foam capsules
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US5146730A (en) * 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US6482516B1 (en) * 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
US5264223A (en) * 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
JPH0427352A (en) * 1990-05-22 1992-01-30 Fuji Capsule Kk Enteric soft capsule for health food
DE4018247A1 (en) 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts MANUFACTURING METHOD FOR QUICK-DISINFITTING FILM-SHAPED PHARMACEUTICAL FORMS
US5164184A (en) * 1990-10-11 1992-11-17 Kim Young S Process for the preparation of pharmaceutical liquid composition containing Bezoar bovis
JPH05245366A (en) * 1992-03-04 1993-09-24 Morishita Jintan Kk Seamless capsule having water-insoluble film in inner side face and its production
MX9301823A (en) * 1992-03-30 1994-01-31 Alza Corp COMPOSITION FOR THE SUPPLY OF CONTROLLED RELEASE OF A BIOLOGICALLY ACTIVE AGENT.
NZ244796A (en) * 1992-08-18 1995-05-26 Scherer Corp R P Capsule shell of soft gelatin contains a medicament and has a removable tab
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
US5431917A (en) * 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5726274A (en) * 1994-12-21 1998-03-10 Basf Corporation Polyurethane polymer or oligomer having carbamate groups, method for its preparation, and coating composition
US20010003647A1 (en) 1995-06-07 2001-06-14 Ji Sun Coreatant-including electrochemiluminescent compounds, methods, systems and kits utilizing same
ID25786A (en) * 1997-12-26 2000-11-02 Warner Lambert Co GELATIN COMPOSITION
AU757343B2 (en) * 1998-09-28 2003-02-20 Capsugel Belgium Nv Enteric and colonic delivery using HPMC capsules
EP1117736B2 (en) * 1998-09-30 2008-08-13 Warner-Lambert Company LLC Modified starch film compositions
EP1072633A1 (en) 1999-07-22 2001-01-31 Warner-Lambert Company Pullulan film compositions
US6346231B1 (en) * 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
EP1186626A1 (en) * 2000-09-05 2002-03-13 Warner-Lambert Company Composition for soluble films with a new hydrolyzed polysaccharide
US6683019B2 (en) * 2001-06-13 2004-01-27 Abb Lummus Global Inc. Catalyst for the metathesis of olefin(s)
KR20100047349A (en) 2001-11-22 2010-05-07 모리시타 진탄 가부시키가이샤 Non-gelatinous capsule film compositions and capsules using the same
NO20021592D0 (en) * 2002-04-04 2002-04-04 Fmc Biopolymer As Polysaccharide Capsules and Method of Preparation thereof
US20040010069A1 (en) 2002-06-27 2004-01-15 Uniroyal Chemical Company, Inc. Rubber compositions and methods for improving the mooney scorch value and cure rate
EP1709958A1 (en) 2002-12-05 2006-10-11 Symrise GmbH & Co. KG Seamless filled capsules
US7396874B2 (en) * 2002-12-06 2008-07-08 Hercules Incorporated Cationic or amphoteric copolymers prepared in an inverse emulsion matrix and their use in preparing cellulosic fiber compositions
CA2510465A1 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
JP4027352B2 (en) 2004-09-17 2007-12-26 アンリツ株式会社 Optical fiber probe device
DE102007039772A1 (en) 2007-08-22 2009-02-26 Cavis Microcaps Gmbh Microcapsule and process for its preparation
JP5245366B2 (en) 2007-11-14 2013-07-24 王子ホールディングス株式会社 Polarizing plate and manufacturing method thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888778A1 (en) * 1997-07-03 1999-01-07 Samyang Corporation Colon selective drug delivery system and compositions comprising said system
EP1132081A2 (en) * 2000-03-06 2001-09-12 Suheung Capsule Co Ltd. Process for preparing cellulose capsule using mixed solution of pectin and glycerin
WO2001070385A2 (en) * 2000-03-17 2001-09-27 Cycolor, Inc. Method for producing microcapsules having improved wall characteristics
US20030166508A1 (en) * 2000-06-07 2003-09-04 Junshou Zhang Biologically active oral preparation that can be site-specific released in colon
US20030175335A1 (en) * 2000-09-01 2003-09-18 Scott Robert Anthony Pectin film compositions
WO2004030658A1 (en) * 2002-10-01 2004-04-15 Banner Pharmacaps, Inc. Enteric composition for the manufacture of soft capsule wall
EP1518552A1 (en) * 2003-09-29 2005-03-30 Suheung Capsule Co Ltd. Fish gelatin hard capsule and its preparation method

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 198351 Derwent Publications Ltd., London, GB; Class A96, AN 1983-847880 XP002900097 -& JP 58 194810 A (MORISHITA JINTAN KK) 12 November 1983 (1983-11-12) *
DATABASE WPI Section Ch, Week 199211 Derwent Publications Ltd., London, GB; Class D13, AN 1992-084752 XP002454379 -& JP 04 027352 A (FUJI CAPSULE KK) 30 January 1992 (1992-01-30) *
DATABASE WPI Section Ch, Week 199343 Derwent Publications Ltd., London, GB; Class J04, AN 1993-339053 XP002454378 -& JP 05 245366 A (MORISHITA JINTAN KK) 24 September 1993 (1993-09-24) *
See also references of EP1973533A2 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197822B2 (en) 2005-11-12 2021-12-14 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8975243B2 (en) 2005-11-12 2015-03-10 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US9119863B2 (en) 2005-11-12 2015-09-01 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US11413296B2 (en) 2005-11-12 2022-08-16 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US9782347B2 (en) 2005-11-12 2017-10-10 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US10272037B2 (en) 2005-11-12 2019-04-30 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US9050368B2 (en) 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions
US11357859B2 (en) 2007-11-13 2022-06-14 Viropharma Biologics Llc Compositions for the treatment of gastrointestinal inflammation
US10293052B2 (en) 2007-11-13 2019-05-21 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US9456991B2 (en) 2011-12-22 2016-10-04 Erik Baes Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
WO2013093630A2 (en) 2011-12-22 2013-06-27 Pronova Biopharma Norge As Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
WO2015066176A1 (en) 2013-10-30 2015-05-07 Banner Life Sciences, LLC Enteric soft capsules comprising polyunsaturated fatty acids
EP3738586A1 (en) 2013-10-30 2020-11-18 Patheon Softgels Inc. Enteric soft capsules comprising polyunsaturated fatty acids
US10357467B2 (en) 2014-06-23 2019-07-23 Patheon Softgels, Inc. All-natural enteric soft capsules
US9987240B2 (en) 2014-06-23 2018-06-05 Patheon Softgels, Inc. All-natural enteric soft capsules
US9782374B2 (en) 2014-06-23 2017-10-10 Patheon Softgels Inc. All-natural enteric soft capsules
CN106456558B (en) * 2014-10-06 2019-10-08 富士胶囊股份有限公司 The preparation method of enteric soft capsules
EP3205338A4 (en) * 2014-10-06 2018-03-21 Fuji Capsule Co., Ltd. Method of producing enteric soft capsule
EP3205339A4 (en) * 2014-10-06 2018-03-14 Fuji Capsule Co., Ltd. Method of producing enteric-coated seamless soft capsule
CN106456558A (en) * 2014-10-06 2017-02-22 富士胶囊股份有限公司 Method of producing enteric soft capsule
US20180353432A1 (en) * 2015-12-09 2018-12-13 Altergon S.A. SOFT GELATIN CAPSULES WITH pH-INDEPENDENT RELEASE
US11304910B2 (en) * 2015-12-09 2022-04-19 Altergon S.A. Soft gelatin capsules with pH-independent release

Also Published As

Publication number Publication date
EP1973533B1 (en) 2015-07-29
JP2009521269A (en) 2009-06-04
US20150024044A1 (en) 2015-01-22
EP2923696B1 (en) 2018-07-11
WO2007075475A3 (en) 2007-12-13
ES2538803T3 (en) 2015-06-24
US20100158958A1 (en) 2010-06-24
CA2633924A1 (en) 2007-07-05
CA2798511C (en) 2015-04-14
US8962005B2 (en) 2015-02-24
EP2716283B1 (en) 2015-04-15
EP1973533A2 (en) 2008-10-01
JP5627854B2 (en) 2014-11-19
CA2633924C (en) 2013-11-19
ES2549858T3 (en) 2015-11-02
JP2013209416A (en) 2013-10-10
CA2798511A1 (en) 2007-07-05
US20170281555A1 (en) 2017-10-05
EP2923696A1 (en) 2015-09-30
US9693966B2 (en) 2017-07-04
US20070148248A1 (en) 2007-06-28
US10182990B2 (en) 2019-01-22
EP2716283A1 (en) 2014-04-09
US9192582B2 (en) 2015-11-24
ES2687807T3 (en) 2018-10-29
US20140072625A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
US10182990B2 (en) Gastric reflux resistant dosage forms
Gullapalli et al. Gelatin and non-gelatin capsule dosage forms
US10342763B2 (en) Chewable soft capsules
US20070082046A1 (en) Enteric valproic acid
WO2006047068A1 (en) Non-blooming gelatin and non-gelatin formulations
CN110891552A (en) Enteric hard capsule
JP2016513674A (en) Silk capsule
JPWO2005011402A1 (en) Chewable capsule and method for producing the same
JP2022123274A (en) Enteric-coated hard capsule
JP2019099473A (en) Soft capsule
US20170281554A1 (en) System for upper intestinal delivery of active ingredients
JPH0710746A (en) Hard capsule agent improved in adhesivity on administration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/007874

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2633924

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008547361

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006845613

Country of ref document: EP